EPI-331 enters human DMD testing
Epicrispr identifies EPI-331 as a utrophin-upregulation approach for Duchenne muscular dystrophy. Its mechanism is distinct from replacing dystrophin and from EPI-321’s FSHD program.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Source establishes mechanism/program identity, not an announced trial date or FDA clearance; eligibility and protocol require later review.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Preclinical development candidate — clinical date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links epicrispr.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The company news index additionally reports its August 2026 Series C close, but financing alone is not used as ownership proof.
Potential outcome market
Will a participant receive EPI-331 in an authorized human DMD trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.